Form 8-K - Current report:
SEC Accession No. 0000950170-23-019727
Filing Date
2023-05-09
Accepted
2023-05-09 16:23:32
Documents
14
Period of Report
2023-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xene-20230509.htm   iXBRL 8-K 67976
2 EX-99.1 xene-ex99_1.htm EX-99 184395
3 GRAPHIC img189401473_0.jpg GRAPHIC 2841
  Complete submission text file 0000950170-23-019727.txt   393970

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xene-20230509_lab.xml EX-101.LAB 17712
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xene-20230509_pre.xml EX-101.PRE 11111
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xene-20230509.xsd EX-101.SCH 2486
8 EXTRACTED XBRL INSTANCE DOCUMENT xene-20230509_htm.xml XML 4688
Mailing Address 200 - 3650 GILMORE WAY BURNABY A1 V5G 48W
Business Address 200 - 3650 GILMORE WAY BURNABY A1 V5G 48W (604) 484-3300
Xenon Pharmaceuticals Inc. (Filer) CIK: 0001582313 (see all company filings)

EIN.: 980661854 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36687 | Film No.: 23902445
SIC: 2834 Pharmaceutical Preparations